Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the “reward center” of the brain. These are the first direct measurements of brain activity in a person receiving tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, shedding light on the treatment’s impact on so-called food noise. The report, published on Monday in Nature Medicine